Actively Recruiting
Characterizing Circulating Biomarker Changes After Different Cancer Treatments in Solid Tumors An Observational Pilot Study
Led by University Hospitals Coventry and Warwickshire NHS Trust · Updated on 2026-09-03
48
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying changes in circulating biomarkers, including miRNAs and proteins, before and after cancer treatments. This study focuses on patients receiving radical radiation therapy or chemoradiotherapy for thoracic cancers and those receiving immuno-oncology-based complex systemic anticancer therapies. The goal is to identify and validate biomarker changes linked to treatment and to explore their relationship with clinical evaluations, especially regarding cardiac or lung toxicity risks. Participants are divided into two groups one receiving radical radiation or concurrent chemoradiotherapy for lung or esophageal cancer, and another receiving immuno-oncology-based combination therapies for various solid tumors. Biomarker profiles are assessed before treatment and after completion of therapy, focusing on over 1,000 protein targets related to immune and inflammatory pathways, as well as miRNA expression patterns. During the study, participants provide blood samples at baseline and at 12 weeks after treatment to measure biomarker changes. The research team evaluates these blood results to understand the effects of treatments. Participants are expected to comply with study procedures and provide informed consent. The study is observational, with no active treatment assigned by the researchers, and it is led by the University Hospitals Coventry and Warwickshire NHS Trust. The total study duration extends until April 2028.
CONDITIONS
Brief Title
Biomarkers for Cancer Treatment
Research Team
H
Hardip Sandhu, MBA, BSc, MSc, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here